The Centers for Medicare & Medicaid Services June 30 released revised guidance detailing how it will implement an Inflation Reduction Act program to negotiate Medicare prices with makers of certain high-cost, single-source drug and biological products in 2023 and 2024 for prices effective in 2026. CMS said it revised the initial March guidance to clarify the drug selection process and how drug companies will participate in the program and expand opportunities for public engagement. 

“For initial price applicability year 2026, CMS does not expect manufacturers to provide access to the [Maximum Fair Price] of a selected drug to hospitals, physicians, and other providers of services and suppliers with respect to a drug furnished or administered to MFP eligible individuals enrolled under Part B, including an individual who is enrolled in an MA [Medicare Advantage] plan,” the guidance states.

The agency plans to publish by Sept. 1 a list of the first 10 Part D drugs selected for price negotiation; host a series of patient-focused listening sessions on the selected drugs this fall; and invite the public to submit data on the selected drugs and therapeutic alternatives by Oct. 2.

Related News Articles

Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District…